The European Society of Endocrinology (ESE) has published a Revised Clinical Practice Guideline for the Treatment of Chronic ...

The European Society of Endocrinology (ESE) has published an open access Revised Clinical Practice Guideline for the ...

Revised Guideline published 10 years after original Guideline, key differences include redefinition and practical treatment ...

The European Society of Endocrinology (ESE) has published an open access Revised Clinical Practice Guideline for the Treatment of Chronic ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera” or the "Company”), a leader in the ...

Ascendis Pharma’s consensus analyst price target has recently increased from $245.61 to $258.77 per share. This reflects a renewed sense of optimism as Yorvipath’s uptake accelerates and real-world ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, ...

Only two days after Bridgebio Pharma Inc. impressed investors with data from BBP-418 in limb-girdle muscular dystrophy type 2I/R9, the company was back at it again, this time reporting positive ...

An Institute for Clinical and Economic Review report concluded that the GLP-1 drugs tirzepatide and semaglutide (Ozempic, ...

BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG), which is impaired in LGMD and causes muscle wasting, initially in the ...